Business
Cell MedX Corp. completes its first observational clinical trial and observes
Cell MedX Corp. completes its first observational clinical trial and observes.
About this update from Stimcell Energetics Inc.
[{"type":"text","content":"Cell MedX Corp. (OTCQB: CMXC), (“Cell MedX” or the “Company”), an early development stage bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, is pleased to announce that the observational clinical trial carried out by Dr. Richard Tytus and his team at Hamilton Medical Research Group in Hamilton, Ontario (the “Trial”) has been completed. Nutrasource Diagnostics Inc., a contract research organization, has completed the final report on the Trial and has submitted it to Health Canada for final approval.The objective of the Trial was to assess eBalance therapy as an adjunct treatment for diabetes and related complications in Type 1 and Type 2 diabetics over three months. The secondary endpoints of the Trial observed changes from baseline in the following;Insulin sensitivityDiabetic neuropathyDiabetic foot pain and numbnessWound healingBlood pressureKidney functionAny other changes reported by patientsThe Company is pleased to announce that all 30 subjects (100%) taking part in the Trial followed through to completion. This level of completion is considered to be unusually high, particularly since the subjects were required to come to the clinic twice a week for a period of three months after the initial screening and selection.The Trial resulted in several encouraging trends spanning a vast array of areas including HbA1c and secondary efficacy endpoints assessing insulin resistance, insulin sensitivity, blood pressure and kidney function following eBalance treatment. On average, the mean HbA1c decreased as compared to baseline. The post-treatment glucometer reading decreased relative to pre-treatment on most visits. A trend towards a decrease in markers assessing insulin resistance including fasting blood glucose, plasma insulin and HbA1c compared to baseline was noted. A marked decrease in blood pressure as measured by systolic and diastolic blood pressure was observed. A decrease in eGFR (estimated glomerular filtration rate used to assess kidney function) was also exhibited. Lastly, in regard to general pain, the Trial revealed that some subjects, without diagnosed complications, reported feeling less pain and/or coldness or numbness in their extremities. During the Trial there were no subjects with di...